<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E69E5317-4F88-42A1-981B-AE5460817436"><gtr:id>E69E5317-4F88-42A1-981B-AE5460817436</gtr:id><gtr:firstName>C</gtr:firstName><gtr:surname>Robinson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FM021750%2F1"><gtr:id>D643EA22-D955-42BC-BC16-89C6CA57DE64</gtr:id><gtr:title>Commercialisation of the Tat protein export pathway for biopharmaceutical production</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M021750/1</gtr:grantReference><gtr:abstractText>Over 30% of licensed therapeutic proteins are made in the bacterium Escherichia coli, where 'export' out of the cytoplasm to the periplasm is a favoured strategy. Current export strategies have severe limitations and we have shown that the 'Tat' export pathway has a number of advantages over traditional systems. The research will enable us to fully commercialise a suite of powerful Tat-based platforms:
1. We will optimise a previously-described system in which expression of a Bacillus subtilis Tat system in an E. coli tat deletion strain leads to export to the periplasm and then release to the medium. We will calibrate the leaky outer membrane phenotype to achieve the optimal balance of cell robustness vs membrane leakiness.
2. We will commercialise a new platform in which biotherapeutics are exported by Tat with disulphide-bonds subsequently formed in the periplasm.
3. We will identify new Tat-based systems that operate more efficiently than the E. coli system.</gtr:abstractText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>181177</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open day presentations</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3DFC9A41-8037-4988-9A2B-906128EE2733</gtr:id><gtr:impact>Hosted open day visits to my lab in majority of UCAS days - 2 groups of UCAS applicants + parents per open day, at least 10 open days per year

Increased understanding of biotech projects at Kent</gtr:impact><gtr:outcomeId>546110f93a1331.38359950</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2009,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We use the Tat protein export system to export high-value proteins to the periplasm in a folded state in E. coli. One aim of this grant is to use Tat systems from different bacteria in place of E. coli's native system. This is because the E. coli system works well, but is relatively slow in transporting proteins. We have now shown that some heterologous Tat systems have excellent potential for exporting biotherapeutics at high rates and we are preparing to patent some of these discoveries.</gtr:description><gtr:exploitationPathways>The aim is to commercialise these findin=gs together with a series of industrial collaborators</gtr:exploitationPathways><gtr:id>3E3D3EF1-97A8-4E1A-ACA1-CA82D1A27332</gtr:id><gtr:outcomeId>56e01d5c72e403.08295048</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed new strains of E. coli that export proteins to the periplasm by a novel pathway</gtr:description><gtr:id>E28FF553-5B0F-41C4-91E7-E5611222C1F5</gtr:id><gtr:impact>Several groups are testing these strains with a view to using them for production production on analytical or production scale</gtr:impact><gtr:outcomeId>56e040f7c18639.50375234</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New E. coli strains</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/M021750/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>